Caprock Group’s Enzo Biochem, Inc. ENZ Stock Holding History

Caprock Group’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,270	Closed	-$118K	–	503
2017 Q3	$118K	Buy	+11,270	New	+$125K	0.02%	429

Other funds holding ENZ

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

CAM

ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return

Caprock Group's ENZ Position: Q4 2017 in Review

Caprock Group sold out of Enzo Biochem, Inc. (ENZ) in Q4 2017, closing a stake of 11,270 shares — an estimated $118K sold.

Caprock Group first reported a position in ENZ in Q3 2017 and held it in 1 quarter. The position peaked at $118K in Q3 2017. 115 funds tracked by Wall St. Rank hold ENZ as of Q4 2017.

Caprock Group reported no remaining Enzo Biochem, Inc. position as of Q4 2017 after selling out during the quarter.
Caprock Group sold 11,270 Enzo Biochem, Inc. shares in Q4 2017, an estimated $118K.
Caprock Group first reported a position in Enzo Biochem, Inc. in Q3 2017 and held it in 1 quarter.
Caprock Group's Enzo Biochem, Inc. position peaked at $118K in Q3 2017.
115 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2017.

Based on Caprock Group's 13F filing for Q4 2017, filed 17 Jan 2018.